Anthropic Drops $6 Billion Decart AI Acquisition Talks 
Oil Prices Surge as Middle East Shipping Attacks Threaten Supply 
Huawei Launches Mate XT2 Foldable Phone in China 
U.S. Accuses Chinese AI Firms of Extracting Model Capabilities 
Zara Owner Inditex Sales Rise 9% in August 
US Treasury Yields Near 5% as Oil Fuels Inflation Fears 
OpenAI Agents Used Websites for Unauthorized Communications 
China Inflation Accelerates in August as CPI, PPI Rise 
Nvidia-Groq AI Chip Deal Faces U.S. Antitrust Probe 
Qualcomm Stock Jumps on Amazon AI Chip Deal 
German Inflation Accelerates to 2.9% in August 
US Bans Canadian Alcohol, Motorcycles as Trade War Escalates 
ECB Rate Hike in Focus as Oil Tops $100 
Fitch Eyes Japan Budget for Fiscal Discipline 
Asian Currencies Subdued as Yen Weakens Ahead of Fed, BOJ Decisions 
Google Revamps EU Search Results to Meet DMA Rules 
Asian Stocks Slide as Oil Surge Fuels Rate Hike Fears 
Add as a preferred source on Google
SK Bioscience recently inked a contract manufacturing organization (CMO) agreement with MSD which is also known as Merck & Co. The deal is for the production of the next-generation Zaire Ebola virus vaccine candidate.
The Vice Minister of the Ministry of Health and Welfare, Park Min Soo, MSD’s executive vice president Sanat Chattopadhyay, SK Bioscience’s chief executive officer Ahn Jae Yong, SK Disocvery’s vice chairman Chang Won Chey, Hillman Labs CEO, Raman Rao, and Representative of Global R&BD Kim Hoon were all present at the signing ceremony.
After the contract signing of the CMO deal with MSD, The Korea Herald reported that the stock price of SK Bioscience surged by 16.39% to KRW83,100 or about $64.04 late last week. The increase is said to be largely due to the hopes that the deal will improve the company’s slow sales performance.
In any case, SK Bioscience further confirmed the deal with MSD on Monday, May 8. It also provided more details about the CMO agreement today.
“For the growth and development of the biopharmaceutical industry, it is very important to promote cooperation between companies and establish its innovative ecosystem,” Park Min Soo said in a press release. “The Korean government is seeking various support measures, such as regulatory innovation and governance establishment, to promote cooperation between companies. We hope that this contract will continue a friendly cooperative relationship between MSD, Korea, and SK bioscience.”
MSD’s EVP and president of the manufacturing unit, Sanat Chattopadhyay, also said, “At MSD, we continue to seek innovative solutions to help expand access and help make our vaccines available when needed to people around the world. This agreement with SK bioscience, as part of our strong global manufacturing network, may enable us to further assist the global community in its response to future outbreaks of the Zaire Ebola virus.”
